Defining disease modification in myelofibrosis in the era of targeted therapy. (2022)
Attributed to:
The Oxford Single Cell Biology Consortium
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1002/cncr.34205
PubMed Identifier: 35499819
Publication URI: http://europepmc.org/abstract/MED/35499819
Type: Journal Article/Review
Volume: 128
Parent Publication: Cancer
Issue: 13
ISSN: 0008-543X